NO20065670L - Kapsel som er stabil mot mastikasjon. - Google Patents
Kapsel som er stabil mot mastikasjon.Info
- Publication number
- NO20065670L NO20065670L NO20065670A NO20065670A NO20065670L NO 20065670 L NO20065670 L NO 20065670L NO 20065670 A NO20065670 A NO 20065670A NO 20065670 A NO20065670 A NO 20065670A NO 20065670 L NO20065670 L NO 20065670L
- Authority
- NO
- Norway
- Prior art keywords
- thickness
- capsule shell
- capsule
- measured
- mastication
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Virology (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Hematology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
Abstract
Myke kapsler som lett desintegreres i magen og hvor man unngår eventuell lekkasje av innholdet ved mastikasjon, hvor disse myke kapsler innkapsler (2R)-2-propyloktansyre eller dens salt og er kjennetegnet ved at der er oppnådd minst en egenskap, foretrukket alle, som er valgt blant (A) styrke på 150 til 400 N som målt ved en spaltingsbelastningstest, (B) desintegreringstid på 3 til 10 min som målt ved en desintegreringstestmetode stipulert i Japanese Pharmacopoeia, (C) tykkelse på 0,05 til 0,50 mm med hensyn til den midtre delen av kapselskallet, (D) tykkelse på 0,10 til 0,55 mm med hensyn til den første sammenføyde delen av kapselskallet, (E) tykkelse på 0,05 til 0,50 mm med hensyn til den andre sammenføyde delen av kapselskallet, og (F) kapselskall-vanninnhold fra 5,0 til 9,0%.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2004174576 | 2004-06-11 | ||
JP2005122821 | 2005-04-20 | ||
PCT/JP2005/011092 WO2005120490A1 (ja) | 2004-06-11 | 2005-06-10 | 咀嚼に対して安定なカプセル |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20065670L true NO20065670L (no) | 2007-03-12 |
Family
ID=35502808
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20065670A NO20065670L (no) | 2004-06-11 | 2006-12-08 | Kapsel som er stabil mot mastikasjon. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20080057115A1 (no) |
EP (1) | EP1754479A4 (no) |
JP (1) | JP5615478B2 (no) |
KR (1) | KR20070024722A (no) |
AU (1) | AU2005251623A1 (no) |
BR (1) | BRPI0512000A (no) |
CA (1) | CA2569746A1 (no) |
IL (1) | IL179967A0 (no) |
MX (1) | MXPA06014396A (no) |
NO (1) | NO20065670L (no) |
RU (1) | RU2384325C2 (no) |
TW (1) | TW200613009A (no) |
WO (1) | WO2005120490A1 (no) |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007123153A1 (ja) * | 2006-04-19 | 2007-11-01 | Ono Pharmaceutical Co., Ltd. | 経口投与用カプセル |
EP2334295B1 (en) | 2008-09-02 | 2017-06-28 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and nicotinic acid and methods of using same |
US9504274B2 (en) * | 2009-01-27 | 2016-11-29 | Frito-Lay North America, Inc. | Methods of flavor encapsulation and matrix-assisted concentration of aqueous foods and products produced therefrom |
US11033523B2 (en) | 2009-04-29 | 2021-06-15 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical compositions comprising EPA and a cardiovascular agent and methods of using the same |
PT3278665T (pt) | 2009-04-29 | 2020-11-19 | Amarin Pharmaceuticals Ie Ltd | Composição farmacêutica estável e métodos de utilização das mesmas |
SG10201708952TA (en) | 2009-06-15 | 2017-12-28 | Ian Osterloh | Compositions and methods for lowering triglycerides without raising ldl-c levels in a subject on concomitant statin therapy |
US20110071176A1 (en) | 2009-09-23 | 2011-03-24 | Amarin Pharma, Inc. | Pharmaceutical composition comprising omega-3 fatty acid and hydroxy-derivative of a statin and methods of using same |
EP2646013A4 (en) | 2010-11-29 | 2014-03-26 | Amarin Pharma Inc | COMPOSITION WITH LOW IMPACT EFFECT AND METHOD FOR THE TREATMENT AND / OR PREVENTION OF CARDIOVASCULAR DISEASES IN A PATIENT WITH FISH ALLERGY / SENSITIVITY |
US11712429B2 (en) | 2010-11-29 | 2023-08-01 | Amarin Pharmaceuticals Ireland Limited | Low eructation composition and methods for treating and/or preventing cardiovascular disease in a subject with fish allergy/hypersensitivity |
WO2012134441A1 (en) * | 2011-03-29 | 2012-10-04 | Empire Technology Development Llc | Microcapsule corrosion control in reinforced concrete |
US20120251484A1 (en) * | 2011-03-31 | 2012-10-04 | Cp Kelco Aps | Cold prepared gel and method for making same |
EP2775837A4 (en) | 2011-11-07 | 2015-10-28 | Amarin Pharmaceuticals Ie Ltd | METHODS OF TREATING HYPERTRIGLYCERIDEMIA |
US11291643B2 (en) | 2011-11-07 | 2022-04-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating hypertriglyceridemia |
ITMI20112221A1 (it) * | 2011-12-05 | 2013-06-06 | Altergon Sa | Formulazioni stabili in capsule di gelatina molle di antiaggreganti piastrinici, acidi grassi omega-3 e amilosio |
AU2013207368A1 (en) | 2012-01-06 | 2014-07-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering levels of high-sensitivity (hs-CRP) in a subject |
LT3363433T (lt) | 2012-06-29 | 2021-02-25 | Amarin Pharmaceuticals Ireland Limited | Širdies ir kraujagyslių sistemos sutrikimų rizikos sumažinimo būdas subjektui, gydomam statinais, panaudojant eikozapentaeno rūgšties etilo esterį |
US20150265566A1 (en) | 2012-11-06 | 2015-09-24 | Amarin Pharmaceuticals Ireland Limited | Compositions and Methods for Lowering Triglycerides without Raising LDL-C Levels in a Subject on Concomitant Statin Therapy |
US20140187633A1 (en) | 2012-12-31 | 2014-07-03 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing nonalcoholic steatohepatitis and/or primary biliary cirrhosis |
US9452151B2 (en) | 2013-02-06 | 2016-09-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing apolipoprotein C-III |
US9624492B2 (en) | 2013-02-13 | 2017-04-18 | Amarin Pharmaceuticals Ireland Limited | Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof |
US9283201B2 (en) | 2013-03-14 | 2016-03-15 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for treating or preventing obesity in a subject in need thereof |
US20140271841A1 (en) | 2013-03-15 | 2014-09-18 | Amarin Pharmaceuticals Ireland Limited | Pharmaceutical composition comprising eicosapentaenoic acid and derivatives thereof and a statin |
CA2911643C (en) | 2013-05-23 | 2018-01-16 | Barlean's Organic Oils, Llc | Rotary die system |
US10966968B2 (en) | 2013-06-06 | 2021-04-06 | Amarin Pharmaceuticals Ireland Limited | Co-administration of rosiglitazone and eicosapentaenoic acid or a derivative thereof |
US20150065572A1 (en) | 2013-09-04 | 2015-03-05 | Amarin Pharmaceuticals Ireland Limited | Methods of treating or preventing prostate cancer |
US9585859B2 (en) | 2013-10-10 | 2017-03-07 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides without raising LDL-C levels in a subject on concomitant statin therapy |
KR101467853B1 (ko) * | 2014-04-01 | 2014-12-03 | 창성소프트젤 주식회사 | 탄성 및 접착성이 우수하고 얇은 피막으로 생산성과 붕해도가 향상되는 식물성 연질캡슐 및 그의 조성물과 그 제조방법 |
US20150335586A1 (en) * | 2014-05-20 | 2015-11-26 | R.P. Scherer Technologies, Llc | Capsule dispensing container |
US10561631B2 (en) | 2014-06-11 | 2020-02-18 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing RLP-C |
WO2015195662A1 (en) | 2014-06-16 | 2015-12-23 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense ldl or membrane polyunsaturated fatty acids |
EP3212152A4 (en) * | 2014-10-31 | 2018-11-07 | Barlean's Organic Oils, LLC | Method and apparatus for the manufacture of softgels |
KR101655407B1 (ko) * | 2015-09-02 | 2016-09-08 | 주식회사 아미코스메틱 | 마이크로 캡슐, 및 마이크로 캡슐을 포함하는 화장료 조성물 |
US10406130B2 (en) | 2016-03-15 | 2019-09-10 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing or preventing oxidation of small dense LDL or membrane polyunsaturated fatty acids |
WO2018213663A1 (en) | 2017-05-19 | 2018-11-22 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject having reduced kidney function |
MX2017016719A (es) * | 2017-12-19 | 2020-01-20 | Alepharma Soc Anonima Promotora De Inversion De Capital Variable | Composición farmacéutica combinada para la prevención de la formación de productos finales de la glicación avanzada. |
US11058661B2 (en) | 2018-03-02 | 2021-07-13 | Amarin Pharmaceuticals Ireland Limited | Compositions and methods for lowering triglycerides in a subject on concomitant statin therapy and having hsCRP levels of at least about 2 mg/L |
SG11202102872QA (en) | 2018-09-24 | 2021-04-29 | Amarin Pharmaceuticals Ie Ltd | Methods of reducing the risk of cardiovascular events in a subject |
KR102412895B1 (ko) | 2020-03-03 | 2022-07-06 | 주식회사 휴온스메디컬 | 시린지의 플런저 고정장치 |
CN114983962B (zh) * | 2021-03-02 | 2024-03-15 | 仙乐健康科技股份有限公司 | 软胶囊囊壳组合物、软胶囊和其制备方法和用途 |
WO2022225896A1 (en) | 2021-04-21 | 2022-10-27 | Amarin Pharmaceuticals Ireland Limited | Methods of reducing the risk of heart failure |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3173840A (en) * | 1962-04-30 | 1965-03-16 | Lilly Co Eli | Separation-resistant capsule |
US3927195A (en) * | 1974-01-31 | 1975-12-16 | Lilly Industries Ltd | Production of capsules |
JPH089536B2 (ja) * | 1987-10-30 | 1996-01-31 | 日清製粉株式会社 | 腸溶性カプセルの製造方法 |
US4954346A (en) * | 1988-06-08 | 1990-09-04 | Ciba-Geigy Corporation | Orally administrable nifedipine solution in a solid light resistant dosage form |
JPH04288011A (ja) * | 1991-03-14 | 1992-10-13 | Tokai Capsule Kk | 軟カプセル剤 |
JPH0565222A (ja) * | 1991-09-09 | 1993-03-19 | Fuji Capsule Kk | カプセル剤用プルラン配合皮膜及びカプセル剤 |
BR9710265A (pt) * | 1996-07-12 | 1999-08-10 | Daiichi Seiyaku Co | Materiais moldados á compressão rapidamente desintegráveis e processo para produção dos mesmos |
JP3261331B2 (ja) * | 1997-03-31 | 2002-02-25 | 東海カプセル株式会社 | 咀嚼用ソフトカプセル剤 |
JP2000128778A (ja) * | 1998-10-20 | 2000-05-09 | Tokai Capsule Kk | 捩じり切り開披型ソフトカプセル |
JP4706950B2 (ja) * | 2000-07-18 | 2011-06-22 | 小野薬品工業株式会社 | アストロサイト機能改善剤を有効成分として含有するパーキンソン病治療剤 |
KR100759771B1 (ko) * | 2000-07-18 | 2007-10-04 | 오노 야꾸힝 고교 가부시키가이샤 | 성상세포 기능 개선제를 유효 성분으로 함유하는 파킨슨병치료제 |
KR20040016991A (ko) * | 2001-07-18 | 2004-02-25 | 오노 야꾸힝 고교 가부시키가이샤 | 뇌허혈 질환 치료제 |
US20050058703A1 (en) * | 2003-08-01 | 2005-03-17 | Chang Robert C. | Gelatin capsules |
SG146687A1 (en) * | 2003-10-03 | 2008-10-30 | Ono Pharmaceutical Co | Drug containing (2r)-2-propyloctanoic acid as the active ingredient |
-
2005
- 2005-06-09 TW TW094119016A patent/TW200613009A/zh unknown
- 2005-06-10 JP JP2006514617A patent/JP5615478B2/ja not_active Expired - Fee Related
- 2005-06-10 RU RU2006147223/15A patent/RU2384325C2/ru not_active IP Right Cessation
- 2005-06-10 CA CA002569746A patent/CA2569746A1/en not_active Abandoned
- 2005-06-10 KR KR1020077000705A patent/KR20070024722A/ko not_active Application Discontinuation
- 2005-06-10 AU AU2005251623A patent/AU2005251623A1/en not_active Abandoned
- 2005-06-10 BR BRPI0512000-4A patent/BRPI0512000A/pt not_active IP Right Cessation
- 2005-06-10 WO PCT/JP2005/011092 patent/WO2005120490A1/ja active Application Filing
- 2005-06-10 MX MXPA06014396A patent/MXPA06014396A/es not_active Application Discontinuation
- 2005-06-10 EP EP05751213A patent/EP1754479A4/en not_active Withdrawn
- 2005-06-10 US US11/629,178 patent/US20080057115A1/en not_active Abandoned
-
2006
- 2006-12-08 NO NO20065670A patent/NO20065670L/no not_active Application Discontinuation
- 2006-12-11 IL IL179967A patent/IL179967A0/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA2569746A1 (en) | 2005-12-22 |
BRPI0512000A (pt) | 2008-01-22 |
EP1754479A1 (en) | 2007-02-21 |
WO2005120490A1 (ja) | 2005-12-22 |
RU2384325C2 (ru) | 2010-03-20 |
MXPA06014396A (es) | 2007-03-12 |
KR20070024722A (ko) | 2007-03-02 |
JP5615478B2 (ja) | 2014-10-29 |
RU2006147223A (ru) | 2008-07-20 |
IL179967A0 (en) | 2007-05-15 |
EP1754479A4 (en) | 2011-03-23 |
AU2005251623A1 (en) | 2005-12-22 |
JPWO2005120490A1 (ja) | 2008-04-03 |
TW200613009A (en) | 2006-05-01 |
US20080057115A1 (en) | 2008-03-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20065670L (no) | Kapsel som er stabil mot mastikasjon. | |
Heaney | Calcium intake and disease prevention | |
Mitea et al. | Efficient degradation of gluten by a prolyl endoprotease in a gastrointestinal model: implications for coeliac disease | |
Montserrat et al. | Influence of dietary components on Aspergillus niger prolyl endoprotease mediated gluten degradation | |
Casanova-Martí et al. | Antihyperglycemic effect of a chicken feet hydrolysate via the incretin system: DPP-IV-inhibitory activity and GLP-1 release stimulation | |
S Abukhadir et al. | Pathogenesis of alcohol-induced osteoporosis and its treatment: a review | |
MX2010000219A (es) | Metodo de procesamiento de carne para aumentar la retencion de humedad. | |
BRPI0414237A (pt) | formulações e métodos para o tratamento de cancer de mama com morinda citrifolia e metilsulfonilmetano | |
TW200509923A (en) | A novel formulation, omeprazole antacid complex-immediate release, for rapid and sustained suppression of gastric acid | |
MX2009012083A (es) | Complemento dietetico para promover la salud y perdida de peso y sus metodos de administracion. | |
US9011843B2 (en) | Formulations including monovalent alginate to enhance effectiveness of administered digestive enzymes | |
Moretti et al. | The obligatory role of host microbiota in bioactivation of dietary nitrate | |
CN102753043A (zh) | 优化膳食酸-碱电位的营养组合物和方法 | |
Fry | Essential biochemistry for medicine | |
NZ600269A (en) | Delivery device for treatment of mastitis | |
EA200602187A1 (ru) | Фармацевтическая композиция и способ её получения | |
WO2009116894A3 (ru) | Кровезаменитель с функцией переноса кислорода, фармацевтическая композиция (варианты) | |
MX2023005450A (es) | Capsulas de gel blando de liberacion retardada. | |
HK1135612A1 (en) | Taste masking system for non-plasticizing drugs | |
MY153109A (en) | A solid pharmaceutical formulation | |
Iwamoto et al. | Influence of gastrectomy on cortical and cancellous bones in rats | |
Wu‐Wong et al. | VS‐501: a novel, nonabsorbed, calcium‐and aluminum‐free, highly effective phosphate binder derived from natural plant polymer | |
Alvito et al. | Applicability of the harmonized in vitro digestion method to titanium dioxide nanomaterials | |
Hurtado Garcia | Pulmonary hypertension: case report | |
Oliveira et al. | The possible management of hypertensive patients infected with COVID-19 through the use of Aliskiren |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application |